PRA-023 Market

“PRA-023 Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about PRA-023 for Ulcerative Colitis in the seven major markets. A detailed picture of the PRA-023 for Ulcerative Colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the PRA-023 for Ulcerative Colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PRA-023 market forecast analysis for Ulcerative Colitis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Ulcerative Colitis.

Drug Summary

Prometheus’ leading clinical candidate, PRA-023, which will be known as MK-7240, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A (TL1A). PRA023 binds both soluble and membrane-associated human TL1A with high affinity and specificity. Prometheus is developing PRA023 to treat immune-mediated diseases, including ulcerative colitis, crohn’s disease, and other autoimmune conditions. It is currently being evaluated in the Phase II trial to assess the safety and efficacy of PRA023 in participants with moderately to severely active ulcerative colitis.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the PRA-023 description, mechanism of action, dosage and administration, research and development activities in Ulcerative Colitis.
• Elaborated details on PRA-023 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PRA-023 research and development activities in Ulcerative Colitis across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around PRA-023.
• The report contains forecasted sales of PRA-023 for Ulcerative Colitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Ulcerative Colitis.
• The report also features the SWOT analysis with analyst views for PRA-023 in Ulcerative Colitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PRA-023 Analytical Perspective by DelveInsight

• In-depth PRA-023 Market Assessment

This report provides a detailed market assessment of PRA-023 for Ulcerative Colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

• PRA-023 Clinical Assessment

The report provides the clinical trials information of PRA-023 for Ulcerative Colitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Ulcerative Colitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PRA-023 dominance.
• Other emerging products for Ulcerative Colitis are expected to give tough market competition to PRA-023 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PRA-023 in Ulcerative Colitis.
• Our in-depth analysis of the forecasted sales data of PRA-023 from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PRA-023 in Ulcerative Colitis.

Key Questions

• What is the product type, route of administration and mechanism of action of PRA-023?
• What is the clinical trial status of the study related to PRA-023 in Ulcerative Colitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PRA-023 development?
• What are the key designations that have been granted to PRA-023 for Ulcerative Colitis?
• What is the forecasted market scenario of PRA-023 for Ulcerative Colitis?
• What are the forecasted sales of PRA-023 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to PRA-023 for Ulcerative Colitis?
• Which are the late-stage emerging therapies under development for the treatment of Ulcerative Colitis